Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Volume 165, Issue -, Pages 1634-1645Publisher
ELSEVIER
DOI: 10.1016/j.ijbiomac.2020.10.016
Keywords
Polyglucose-sorbitol-carboxymethyl ether; Antioxidant; Iron accumulation
Funding
- Projects of International Cooperation and Exchanges NSFC [81420108021]
- NSFC [81730067, 81572195]
- Excellent Young Scholars NSFC [81622033]
- Major Research Plan of NSFC [81991514]
- Youth Thousand Talents Program of China [13004001]
- Research Team Start-up Funds of Nanjing University [14912203]
- National Natural Science Foundation of China (NSFC) [81802135]
- Jiangsu Provincial KeyMedical Center Foundation
- Jiangsu ProvincialMedical Outstanding Talent Foundation
- Jiangsu Provincial Medical Youth Talent Foundation
- Jiangsu Provincial Key Medical Talent Foundation
- Key Technologies R&D Programof Jiangsu Province [BE2018010-3]
Ask authors/readers for more resources
In this work, the biological polysaccharide-based antioxidant polyglucose-sorbitol-carboxymethyl ether (PSC) was used as the precursor to synthesize Fe2O3@PSC nanoparticles, which are expected to scavenge excess reactive oxygen species (ROS) to inhibit osteogenesis and promote osteoclast differentiation in iron accumulation (IA)-related osteoporosis. The Fe2O3@PSC nanoparticles obtained were of a uniform particle size of 7.3 nm with elemental O/Fe/Cl/C at a ratio of 190:7:2:88. In addition, the Fe2O3@PSC nanoparticles showed the ability to supply equivalent amounts of iron as the typical iron agent ferric ammonium citrate (FAC) in vitro and in vivo. Importantly, the Fe2O3@PSC nanoparticles not only induced antioxidative MC3T3-E1 and Raw 264.7 cells to scavenge ROS but also promoted osteogenic differentiation by activating Akt-GSK-3 beta-beta-catenin and inhibiting osteoclast differentiation by inhibiting the MAPK and NF-kappa B pathways in vitro. In vivo, no IA-related osteoporosis was induced in a mouse model when enough iron was supplied by the Fe2O3@PSC nanoparticles. Overall, the biological polysaccharide-based antioxidant PSC can supply iron and prevent IA-related osteoporosis, indicating that it is a promising novel iron agent for applications to treat iron deficiency diseases. (C) 2020 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available